The PE Ratio as of November 2024 (TTM) for Syros Pharmaceuticals, Inc. (SYRS) is -0.10

According to Syros Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.10. This represents a change of -97.95% compared to the average of -4.88 of the last 4 quarters.

Syros Pharmaceuticals, Inc. (SYRS) Historical PE Ratio (quarterly & annually)

How has SYRS PE Ratio performed in the past?

The mean historical PE Ratio of Syros Pharmaceuticals, Inc. over the last ten years is -2.96. The current -0.10 PE Ratio has changed 237.80% with respect to the historical average. Over the past ten years (40 quarters), SYRS's PE Ratio was at its highest in in the December 2022 quarter at 0.90. The PE Ratio was at its lowest in in the March 2015 quarter at -17.83.

Syros Pharmaceuticals, Inc. (SYRS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Syros Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Syros Pharmaceuticals, Inc. (SYRS) Average PE Ratio

How has SYRS PE Ratio performed in the past?

The current PE Ratio of Syros Pharmaceuticals, Inc. (SYRS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Syros Pharmaceuticals, Inc. (SYRS) PE Ratio vs. Peers

How is SYRS’s PE Ratio compared to its peers?

Syros Pharmaceuticals, Inc.’s PE Ratio is greater than Surrozen, Inc. (-0.66), greater than Bolt Biotherapeutics, Inc. (-0.34), greater than Larimar Therapeutics, Inc. (-6.07), greater than Keros Therapeutics, Inc. (-11.12), greater than Kezar Life Sciences, Inc. (-5.71), greater than IDEAYA Biosciences, Inc. (-12.96), greater than Syndax Pharmaceuticals, Inc. (-4.63), greater than Xencor, Inc. (-8.08), greater than REGENXBIO Inc. (-2.04), greater than Crinetics Pharmaceuticals, Inc. (-16.16), greater than Black Diamond Therapeutics, Inc. (-1.96), greater than Stoke Therapeutics, Inc. (-6.11), less than Homology Medicines, Inc. (-0.01), greater than Harpoon Therapeutics, Inc. (-122.60), greater than Passage Bio, Inc. (-0.45), less than Pasithea Therapeutics Corp. (-0.00), greater than Kronos Bio, Inc. (-0.64), greater than Quoin Pharmaceuticals, Ltd. (-0.33), greater than RenovoRx, Inc. (-3.51), less than Spero Therapeutics, Inc. (21.41), greater than Coherus BioSciences, Inc. (-279.06), greater than Gracell Biotechnologies Inc. (-29.05), greater than Neoleukin Therapeutics, Inc. (-5.86),

Build a custom stock screener for Syros Pharmaceuticals, Inc. (SYRS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Syros Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Syros Pharmaceuticals, Inc. (SYRS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Syros Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.